Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Future Lipitor spokesman?

Executive Summary

During House Budget hearing March 7, Rep. Gutknecht (R-Minn.) asked HHS Secretary Thompson about a letter sent to a senior citizen who imported Pfizer's cholesterol drug Lipitor for personal use, quoting it as saying "this article appears to be a new drug without an approved NDA." Thompson responded, "I want to find out about those letters because I personally take Lipitor. It better be an approved drug or else my doctor is in trouble"

You may also be interested in...



State Block Grants Possible in 2002 If Medicare Reform Fails This Year - Tauzin

Congress will consider a state block grant drug benefit in 2002 if a Medicare reform package does not pass this year, House Energy & Commerce Committee Chairman Tauzin (R-La.) predicted during a March 22 media briefing.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS037470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel